The fatty acid composition of plasma cholesteryl esters and estimated desaturase activities in patients with nonalcoholic fatty liver disease and the effect of long-term ezetimibe therapy on these levels

Clinica Chimica Acta

Volumn 411, Issue 21-22, 2010, Pages 1735-1740

  Park, Hyohun ^a,b   Hasegawa, Goji ^b   Shima, Toshihide ^a   Fukui, Michiaki ^b   Nakamura, Naoto ^b   Yamaguchi, Kanji ^b   Mitsuyoshi, Hironori ^b   Minami, Masahito ^b   Yasui, Kohichiroh ^b   Itoh, Yoshito ^b   Yoshikawa, Toshikazu ^b   Kitawaki, Jo ^c   Ohta, Mitsumiro ^d   Obayashi, Hiroshi ^e   Okanoue, Takeshi ^a,b  

^a Saiseikai Imperial Gift Foundation Inc Saiseikai Suita Hospital   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^d KOBE PHARMACEUTICAL UNIVERSITY   (Japan)

^e Institute of Bio Response Informatics   (Japan)

Author keywords

Ezetimibe; Fatty acid component; Insulin resistance; Lipid metabolism; Metabolic syndrome; Nonalcoholic fatty liver disease

Indexed keywords

ACYL COENZYME A DESATURASE; ACYL COENZYME A DESATURASE 1; CHOLESTEROL ESTER; EZETIMIBE; GAMMA LINOLENIC ACID; LINOLEOYL COENZYME A DESATURASE; PALMITIC ACID; PALMITOLEIC ACID;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; LIPID COMPOSITION; LIVER HISTOLOGY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AZETIDINES; CASE-CONTROL STUDIES; CHOLESTEROL ESTERS; FATTY ACID DESATURASES; FATTY ACIDS; FATTY LIVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 77956485145     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.07.012     Document Type: Article

References (40)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002, 18:1221-1231.
2. Browning J.D., Szczepaniak L.S., Dobbins R., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40:1387-1395.
3. Farrell G.C. Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region?. J Gastroenterol Hepatol 2003, 18:124-138.
4. Chitturi S., Abeygunasekera S., Farrell G.C., et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002, 35:373-379.
5. Sanyal A.J., Campbell-Sargent C., Mirshahi F., et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001, 120:1183-1192.
6. Day C.P., James O.F. Steatohepatitis: a tale of two "hits"?. Gastroenterology 1998, 114:842-845.
7. Schaffer J. Lipotoxicity: when tissues overeat. Curr Opin Lipidol 2003, 14:281-287.
8. Yu C.C.Y., Cline G.W., Zong H., et al. Mechanism by which fatty acids inhibit insulin activation of insulin receptor dubstrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem 2002, 277:50230-50236.
9. Joshi-Barve S., Barve S.S., Amancherla K., et al. Palmitic acid induces production of proinflammatory cytokine interleukin-8 from hepatocytes. Hepatology 2007, 46:823-830.
10. Park T., Hu Y., Noh H., et al. Ceramide is a cardiotoxin in lipotoxic cardiomyopathy. J Lipid Res 2008, 49:2101-2112.
11. Haus J., Kashyap S., Kasumov T., et al. Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance. Diabetes 2009, 58:337-344.
12. Puri P., Baillie R.A., Wiest M.M., et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 2007, 46:1081-1090.
13. Araya J., Rodrigo R., Videla L.A., et al. Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci (Lond) 2004, 106:635-643.
14. Vessby B., Gustafsson I.B., Tengblad S., Boberg M., Andersson A. Desaturation and elongation of fatty acids and insulin action. Ann NY Acad Sci 2002, 967:183-195.
15. Wang L., Folsom A.R., Zheng Z.J., Pankow J.S. ARIC Study Investigators. Plasma fatty acid composition and incidence of diabetes in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Clin Nutr 2003, 78:91-98.
16. Laaksonen D.E., Lakka T.A., Lakka H.M., et al. Serum fatty acid composition predicts development of impaired fasting glycaemia and diabetes in middle-aged men. Diabet Med 2002, 19:456-464.
17. Vessby B. Dietary fat, fatty acid composition in plasma and the metabolic syndrome. Curr Opin Lipidol Feb 2003, 14:15-19.
18. Warensjö E., Ohrvall M., Vessby B. Fatty acid composition and estimated desaturase activities are associated with obesity and lifestyle variables in men and women. Nutr Metab Cardiovasc Dis Mar 2006, 16:128-136.
19. Puri P., Wiest M.M., Cheung O., et al. The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology 2009, 50:1827-1838.
20. de Almeida I.T., Cortez-Pinto H., Fidalgo G., Rodrigues D., Camilo M.E. Plasma total and free fatty acids composition in human non-alcoholic steatohepatitis. Clin Nutr 2002, 21:219-223.
21. Labonté E.D., Camarota L.M., Rojas J.C., et al. Reduced absorption of saturated fatty acids and resistance to diet-induced obesity and diabetes by ezetimibe-treated and Npc1l1-/- mice. Am J Physiol Gastrointest Liver Physiol 2008, 295:G776-G783.
22. Kleiner D.E., Brunt E.M., Van Natta M., et al. Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1313-1321.
23. Bligh E.G., Dyer W.J. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959, 37:911-917.
24. Hasegawa G., Kajiyama S., Tanaka T., et al. The alpha-glucosidase inhibitor acarbose reduces the net electronegative charge of low-density lipoprotein in patients with newly diagnosed type 2 diabetes. Clin Chim Acta 2008, 390:110-114.
25. Steinbrecher U.P., Witztum J.L., Parthasarathy S., Steinberg D. Decrease in reactive amino groups during oxidation or endothelial cell modification of LDL: correlation with changes in receptor-mediated catabolism. Arteriosclerosis 1987, 7:135-143.
26. Steinbrecher U.P. Oxidation of human low density lipoprotein results in derivatization of lysine residues of apolipoprotein B by lipid peroxide decomposition products. J Biol Chem 1987, 262:3603-3608.
27. Miyazaki A., Sakai M., Suginohara Y., et al. Acetylated low density lipoprotein reduces its ligand activity for the scavenger receptor after interaction with reconstituted high density lipoprotein. J Biol Chem 1994, 269:5264-5269.
28. Wei Y., Wang D., Topczewski F., Pagliassotti M.J. Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells. Am J Physiol Endocrinol Metab 2006, 291:E275-E281.
29. Pagliassotti M.J., Wei Y., Wang D. Insulin protects liver cells from saturated fatty acid-induced apoptosis via inhibition of c-Jun NH2 terminal kinase activity. Endocrinology 2007, 148:3338-3345.
30. Malhi H., Bronk S.F., Werneburg N.W., Gores G.J. Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J Biol Chem 2006, 281:12093-12101.
31. Nakamura M.T., Nara T.Y. Structure, function, and dietary regulation of delta6, delta5, and delta9 desaturases. Annu Rev Nutr 2004, 24:345-376.
32. Miyazaki M., Kim Y.C., Gray-Keller M.P., Attie A.D., Ntambi J.M. The biosynthesis of hepatic cholesterol esters and triglycerides is impaired in mice with a disruption of the gene for stearoyl-CoA desaturase 1. J Biol Chem 2000, 275:30132-30138.
33. Attie A.D., Krauss R.M., Gray-Keller M.P., et al. Relationship between stearoyl-CoA desaturase activity and plasma triglycerides in human and mouse hypertriglyceridemia. J Lipid Res 2002, 43:1899-1907.
34. Borkman M., Storlien L.H., Pan D.A., et al. The relation between insulin sensitivity and the fatty acid composition of skeletal-muscle phospholipids. N Engl J Med 1993, 328:238-244.
35. Pan D.A., Lillioja S., Milner M.R., et al. Skeletal muscle membrane lipid composition is related to adiposity and insulin action. J Clin Invest 1995, 96:2802-2808.
36. Wahl H.G., Kausch C., Machicao F., Rett K., Stumvoll M., Häring H.U. Troglitazone downregulates delta-6 desaturase gene expression in human skeletal muscle cell cultures. Diabetes 2002, 51:1060-1065.
37. Rimoldi O.J., Finarelli G.S., Brenner R.R. Effects of diabetes and insulin on hepatic delta 6 desaturase gene expression. Biochem Biophys Res Commun 2001, 283:323-326.
38. Garcia-Calvo M., Lisnock J., Bull H.G., et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci USA 2005, 102:8132-8137.
39. Deushi M., Nomura M., Kawakami A., et al. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. FEBS Lett 2007, 581:5664-5670.
40. Zheng S., Hoos L., Cook J., et al. Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice. Eur J Pharmacol 2008, 584:118-124.